Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review
Titel:
Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review
Auteur:
Young, Guy Pipe, Steven W. Kenet, Gili Oldenburg, Johannes Safavi, Mariam Czirok, Tuende Nissen, Francis Mahlangu, Johnny
Verschenen in:
Research and practice in thrombosis and haemostasis